About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Hematological Oncology
›
top-articles
Hematological Oncology
2.0
(top 20%)
impact factor
2.8K
(top 10%)
papers
28.4K
(top 10%)
citations
62
(top 10%)
h
-index
2.7
(top 20%)
impact factor
4.8K
all documents
30.6K
doc citations
89
(top 10%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
Growth fractions in malignant non‐Hodgkin's lymphomas (NHL) as determined
in situ
with the monoclonal antibody Ki‐67
Hematological Oncology
1984
302
2
Managing the toxicities of CAR T‐cell therapy
Hematological Oncology
2019
214
3
Clinical and prognostic relevance of the Kiel classification of non‐Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group
Hematological Oncology
1984
198
4
Criteria for the cytologic subclassification of follicular lymphomas: A Proposed alternative method
Hematological Oncology
1983
185
5
PRESENCE OF EPSTEIN-BARR VIRUS DNA IN NASAL LYMPHOMAS OF B AND ‘T’ CELL TYPE
Hematological Oncology
1990
177
6
Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis
Hematological Oncology
1989
172
7
Multiple myeloma: Every year a new standard?
Hematological Oncology
2019
155
8
Prognostic impact of tumour‐infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma
Hematological Oncology
2009
153
9
Angiotropic large cell lymphoma (ALCL): Morphological, immunohistochemical and genotypic studies with analysis of previous reports
Hematological Oncology
1989
147
10
Pathophysiology of acute graft-versus-host disease
Hematological Oncology
2003
145
11
Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis
Hematological Oncology
2005
136
12
Extranodal NK/T‐cell lymphoma: diagnosis and treatment cues
Hematological Oncology
2008
135
13
Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy
Hematological Oncology
2007
134
14
Intravascular lymphoma: a neoplasm of ‘homeless’ lymphocytes?
Hematological Oncology
2006
132
15
The dog as a possible animal model for human non‐Hodgkin lymphoma: a review
Hematological Oncology
2013
132
16
CAR T‐cell therapy: Full speed ahead
Hematological Oncology
2019
131
17
Ophthalmologic and intraocular non-Hodgkin's lymphoma: a large single centre study of initial characteristics, natural history, and prognostic factors
Hematological Oncology
2004
129
18
Nucleophosmin (
NPM1
) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity
Hematological Oncology
2009
127
19
Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial
Hematological Oncology
2009
125
20
Rapid and complete hemopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high dose chemo-radiotherapy?
Hematological Oncology
1989
119
21
Hepatitis B infection in patients with lymphomas
Hematological Oncology
1990
119
22
Natural killer cell lymphoma/leukemia: pathology and treatment
Hematological Oncology
1997
119
23
Modifications in the classification of primary myelodysplastic syndromes: The addition of a scoring system
Hematological Oncology
1985
114
24
The new World Health Organization classification of lymphomas: the past, the present and the future
Hematological Oncology
2001
111
25
Richter syndrome: molecular insights and clinical perspectives
Hematological Oncology
2009
109
26
Secondary hemophagocytic syndrome in adults: a case series of 18 patients in a single institution and a review of literature
Hematological Oncology
2011
98
27
Hypermethylation of gene promoters in hematological neoplasia
Hematological Oncology
2002
97
28
Rituximab monotherapy is highly effective in splenic marginal zone lymphoma
Hematological Oncology
2007
96
29
Update on the molecular biology of mantle cell lymphoma
Hematological Oncology
2006
89
30
Genetic and phenotypic analysis of B‐cell post‐transplant lymphoproliferative disorders provides insights into disease biology
Hematological Oncology
2008
89
31
The use of droplet digital PCR in liquid biopsies: A highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid
Hematological Oncology
2018
86
32
Epidemiology Of Hodgkin's disease: a review
Hematological Oncology
2004
84
33
Secondary central nervous system involvement by non-Hodgkin's lymphoma: The risk factors
Hematological Oncology
2006
82
34
High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma
Hematological Oncology
2015
82
35
ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R
2
‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma
Hematological Oncology
2019
82
36
Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake
Hematological Oncology
2006
81
37
When epigenetics kills: MLL fusion proteins in leukemia
Hematological Oncology
2005
80
38
Serum albumin level at diagnosis of diffuse large B‐cell lymphoma: an important simple prognostic factor
Hematological Oncology
2016
80
39
Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis
Hematological Oncology
1993
79
40
Fertility preservation after chemotherapy for Hodgkin lymphoma
Hematological Oncology
2010
79
41
Potential role for low dose limited-field radiation therapy (2 × 2 grays) in advanced low-grade non-Hodgkin's lymphomas
Hematological Oncology
1994
78
42
Role of Bcl-2 family of proteins in malignancy
Hematological Oncology
2002
78
43
Treatment of early chronic lymphocytic leukemia: Intermittent chlorambucil versus observation
Hematological Oncology
1988
77
44
The 2016 updated WHO classification of lymphoid neoplasias
Hematological Oncology
2017
75
45
A phase 1a clinical trial of LYM-1 monoclonal antibody serotherapy in patients with refractory b cell malignancies
Hematological Oncology
1989
74
46
Evidence for the detection of the normal counterpart of hodgkin and sternberg‐reed cells
Hematological Oncology
1983
74
47
Radiation therapy for localized low-grade non-Hodgkin's lymphomas
Hematological Oncology
2005
73
48
Prognostic factors for primary gastrointestinal lymphoma
Hematological Oncology
1995
72
49
ABCG2 (BCRP) expression in normal and malignant hematopoietic cells
Hematological Oncology
2003
72
50
The root of many evils: indolent large granular lymphocyte leukaemia and associated disorders
Hematological Oncology
2010
71
site/software ©
exaly
; All materials licenced under
CC by-SA
.